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Today, transcatheter therapy offers a valuable therapeutic option for high-risk patients with aortic-, pulmonic-and mitral valve disease. Since Bonhoeffers pioneer achievement, multiple novel percutaneous devices and treatment approaches have been developed, some of them resolving the shortcomings and limitations of earlier devices and procedures. The present report examines these emerging devices for transcatheter aortic valve replacement and also focuses on novel percutaneous options for mitral-and tricuspid valve disease. In the future, these transcatheter approaches are expected to offer less invasive and safer treatment for valvular heart disease and thus expand the therapeutic options particularly for elderly patients.
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